Navigation Links
Mixed Results Seen With 'Off-Label' Use of Antipsychotics
Date:9/27/2011

TUESDAY, Sept. 27 (HealthDay News) -- Even though off-label use of atypical antipsychotic drugs is common, a new review finds that such use is only effective in a few conditions and can be harmful in others.

Also known as "second-generation" antipsychotics, these drugs are approved in the United States for treatment of schizophrenia, bipolar disorder and depression. But off-label use -- or use not approved by the U.S. Food and Drug Administration -- of these drugs to treat a number of other conditions is growing.

Researchers analyzed findings from 393 clinical studies to gauge effectiveness and uncover harmful side effects when Risperdal, Zyprexa, Seroquel, Abilify, Geodon, Saphris, Fanapt and Invega were used outside of FDA-approved indications.

Off-label use included treatment for behavioral symptoms in dementia, anxiety, depression, obsessive-compulsive disorder, eating disorders, post-traumatic stress disorder, insomnia, personality disorders and substance abuse.

The investigators found that Abilify (aripiprazole), Zyprexa (olanzapine) and Risperdal (risperidone) were associated with small but statistically significant benefits for elderly people with dementia symptoms, such as aggression, psychosis and mood changes.

Seroquel (quetiapine) was 26 percent more effective than placebo in people with generalized anxiety disorder, and Risperdal was four times more effective than placebo in people with obsessive-compulsive disorder.

There was no evidence that atypical antipsychotics benefited people with substance abuse or eating disorders, according to Dr. Alicia Ruelaz Maher, of RAND Health in Santa Monica, Calif., and colleagues.

The researchers also found that certain atypical antipsychotics increased the risk of death, stroke, movement disorders and urinary tract symptoms in elderly patients. In younger patients, some of the drugs caused problems such as weight gain, fatigue, sedation, and akathisia, also known as restless leg syndrome.

The study is published in the Sept. 28 issue of the Journal of the American Medical Association.

"The benefits and harms vary among atypical antipsychotic medications for off-label use," the researchers concluded in a journal news release. "This evidence should prove useful for clinicians considering off-label prescribing of atypical antipsychotic medications, and should contribute to optimal treatment decision making for individual patients with specific clinical symptoms and unique risk profiles."

More information

The U.S. National Institute of Mental Health has more about mental health medications.

-- Robert Preidt

SOURCE: Journal of the American Medical Association, news release, Sept. 27, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Bone drug is mixed blessing for breast cancer patients
2. Trials of Type 1 Diabetes Vaccines Bring Mixed Results
3. Models Photos May Spur Mixed Messages About Body Image
4. Americas Health a Mixed Bag: Report
5. Elder law expert: Health care reform act a mixed bag for seniors
6. Antibiotics a Mixed Bag for Kids Ear Infections: Analysis
7. U.S. Report on Kids Health Brings Mixed Results
8. Extending lifespan has mixed effects on learning and memory
9. Company stock prices before public announcements of oncology trial results
10. Check Plastic Surgeons Credentials or Risk Tragic Results, Experts Warn
11. Parents anxiety about newborn screening results does not lead to increased health care use
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Mixed Results Seen With 'Off-Label' Use of Antipsychotics
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for professional women, ... towards gender equality at their inaugural Summit in New York City in June. The ... social audience of over 3 million. To watch the Mobilize Women video, click ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to ... to save lost souls in the Philippines. “The Journey: From the Mountains to the ... teacher of the Bible. She has taught all ages and currently teaches a class ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company ... of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every ... meet the highest standard. , These products are also: Gluten Free, Non-GMO, ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... Hair Restoration, has recently contributed a medical article to the newly revamped ... Dr. Mohebi’s article spotlights the hair transplant procedure known as Follicular Unit ...
(Date:10/12/2017)... ... 12, 2017 , ... Health Literacy Innovations (HLI), creator of ... and the Cancer Patient Education Network (CPEN), an independent professional organization that shares ... strategic alliance. , As CPEN’s strategic partner, HLI will help support CPEN ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... received FDA 510(k) clearance in May 2017 for its highly anticipated ... for endoscopy environments. An innovative secondary monitor solution, ZeroWire Mobile ... the improvement of patient outcomes, procedural efficiency, and the lowering of ... ... By ...
(Date:10/5/2017)... Ill. , Oct. 5, 2017  In ... Association of Oral and Maxillofacial Surgeons (AAOMS) released ... opioids – to be used as a first-line ... pain. Recognizing ... the AAOMS White Paper "Opioid Prescribing: Acute and ...
(Date:10/4/2017)... OBP Medical , a leading ... today announced regulatory approval from Brazil,s ... Nacional de Vigilância Sanitária (ANVISA)) to market ... with integrated LED light source and smoke evacuation ... of a tissue pocket or cavity during surgical ...
Breaking Medicine Technology: